Halozyme Therapeutics shares traded higher Friday, April 17, 2026, extending a recent upswing as investors reacted to a string of upbeat analyst updates that lifted valuation targets and reinforced the company’s 2026 growth narrative. The latest high-profile move circulating in market chatter is a Morgan Stanley price-target increase to $94 from $78 while maintaining an Overweight stance, pointing to expectations for another strong year driven by royalty revenues and continued ENHANZE partnership expansion alongside progress in newer platforms such as Hypercon and Surf Bio. (tipranks.com)

Halozyme’s story remains centered on monetizing its ENHANZE drug-delivery technology via royalties tied to partner products, a model that has produced record results and supports management’s multi-year guidance framework. The company’s most recent full-year update highlighted record 2025 revenue and reiterated 2026 financial guidance, keeping the spotlight on sustained royalty growth from established ENHANZE-enabled products and incremental upside from new collaboration wins. (prnewswire.com)

Near-term catalysts shift back to execution and deal cadence: investors will track whether Halozyme can add incremental ENHANZE and/or Hypercon agreements during 2026, as outlined in recent company communications, and whether partner commercialization trends continue to lift royalty streams. Leadership transition headlines also remain in view following the appointment of an interim CFO effective March 23, 2026, though today’s price action appears more tied to refreshed bullish sell-side positioning than to a new corporate filing. (prnewswire.com)